Lenalidomide is a drug clinically active in CLL and with manageable toxicity.
Lenalidomide targets both CLL cells and their interactions with microenvironment.
Lenalidomide counteracts the immunosuppressive attitude of CLL microenvironment.
Lenalidomide could be a core platform for combinations with new TKIs in CLL.